Sofie Deschoemaeker

1.7k total citations · 1 hit paper
14 papers, 1.0k citations indexed

About

Sofie Deschoemaeker is a scholar working on Cancer Research, Molecular Biology and Immunology. According to data from OpenAlex, Sofie Deschoemaeker has authored 14 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Cancer Research, 6 papers in Molecular Biology and 6 papers in Immunology. Recurrent topics in Sofie Deschoemaeker's work include Cancer, Hypoxia, and Metabolism (8 papers), Immunotherapy and Immune Responses (3 papers) and Immune cells in cancer (3 papers). Sofie Deschoemaeker is often cited by papers focused on Cancer, Hypoxia, and Metabolism (8 papers), Immunotherapy and Immune Responses (3 papers) and Immune cells in cancer (3 papers). Sofie Deschoemaeker collaborates with scholars based in Belgium, Germany and Finland. Sofie Deschoemaeker's co-authors include Massimiliano Mazzone, Mathias Wenes, Andrea Casazza, Damya Laoui, Sabrina Rizzolio, Marco Mambretti, Luca Tamagnone, Jo A. Van Ginderachter, Nicklas Bassani and Giusy Di Conza and has published in prestigious journals such as Cancer Cell, Cancer Research and Oncogene.

In The Last Decade

Sofie Deschoemaeker

14 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Impeding Macrophage Entry into Hypoxic Tumor Areas by Sema3A/Nrp1 Signaling Blockade Inhibits Angiogenesis and Restores Antitumor Immunity

2013 477 citations Andrea Casazza, Damya Laoui et al. Cancer Cell profile →

Peers

Sofie Deschoemaeker

MB

IMMUN

CR

ONCOL

BE

Radia Marie Johnson Canada

Lucia Borriello United States

Veronica Finisguerra Belgium

Defeng Deng United States

Kara White Moyes United States

Jean‐Philippe Brosseau Canada

Nicklas Bassani United States

Alvaro G. Alvarado United States

Sabrina Rizzolio Italy

Barbara Blouw United States

Radia Marie Johnson Canada

Sofie Deschoemaeker

633 ×1.2

MB

290 ×0.7

IMMUN

330 ×0.8

CR

283 ×0.9

ONCOL

51 ×0.6

BE

Citations per year, relative to Sofie Deschoemaeker Sofie Deschoemaeker (= 1×) peers Radia Marie Johnson

Countries citing papers authored by Sofie Deschoemaeker

Since Specialization

Citations

This map shows the geographic impact of Sofie Deschoemaeker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sofie Deschoemaeker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sofie Deschoemaeker more than expected).

Fields of papers citing papers by Sofie Deschoemaeker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sofie Deschoemaeker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sofie Deschoemaeker. The network helps show where Sofie Deschoemaeker may publish in the future.

Co-authorship network of co-authors of Sofie Deschoemaeker

This figure shows the co-authorship network connecting the top 25 collaborators of Sofie Deschoemaeker. A scholar is included among the top collaborators of Sofie Deschoemaeker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sofie Deschoemaeker. Sofie Deschoemaeker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

1.

Kancheva, Daliya, Ayla Debraekeleer, Pauline M. R. Bardet, et al.. (2023). Flt3L therapy increases the abundance of Treg-promoting CCR7+ cDCs in preclinical cancer models. Frontiers in Immunology. 14. 1166180–1166180. 5 indexed citations

2.

Deschoemaeker, Sofie, Geert Raes, Anke Maes, et al.. (2022). Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions. International Journal of Molecular Sciences. 23(2). 904–904. 30 indexed citations

3.

Deschoemaeker, Sofie, et al.. (2022). Dendritic Cell Vaccines: A Promising Approach in the Fight against Ovarian Cancer. Cancers. 14(16). 4037–4037. 20 indexed citations

4.

Hadadi, Éva, et al.. (2022). Heterogeneity and function of macrophages in the breast during homeostasis and cancer. International review of cell and molecular biology. 367. 149–182. 2 indexed citations

5.

Stornetta, Alessia, Peter W. Villalta, Sofie Deschoemaeker, et al.. (2022). In Vivo Identification of Adducts from the New Hypoxia-Activated Prodrug CP-506 Using DNA Adductomics. Chemical Research in Toxicology. 35(2). 275–282. 11 indexed citations

6.

Jordan, Bénédicte F., et al.. (2018). Impact of myo‐inositol trispyrophosphate (ITPP) on tumour oxygenation and response to irradiation in rodent tumour models. Journal of Cellular and Molecular Medicine. 23(3). 1908–1916. 12 indexed citations

7.

Niemans, Raymon, Ala Yaromina, Jan Theys, et al.. (2018). EP-2327: Hypoxic cell killing by CP-506, a novel hypoxia-activated prodrug. Radiotherapy and Oncology. 127. S1283–S1284. 1 indexed citations

8.

Thiolloy, Sophie, Sofie Deschoemaeker, Ludwig J. Dubois, et al.. (2018). Abstract 4959: CP-506, a next generation hypoxia-activated prodrug, as promising novel anti-cancer therapeutic. Cancer Research. 78(13_Supplement). 4959–4959. 3 indexed citations

9.

Conza, Giusy Di, Stefan Loroch, Daniela Mennerich, et al.. (2017). The mTOR and PP2A Pathways Regulate PHD2 Phosphorylation to Fine-Tune HIF1α Levels and Colorectal Cancer Cell Survival under Hypoxia. Cell Reports. 18(7). 1699–1712. 95 indexed citations

10.

Deschoemaeker, Sofie, Giusy Di Conza, Sérgio Lilla, et al.. (2015). PHD 1 regulates p53‐mediated colorectal cancer chemoresistance. EMBO Molecular Medicine. 7(10). 1350–1365. 44 indexed citations

11.

Casazza, Andrea, Damya Laoui, Mathias Wenes, et al.. (2013). Impeding Macrophage Entry into Hypoxic Tumor Areas by Sema3A/Nrp1 Signaling Blockade Inhibits Angiogenesis and Restores Antitumor Immunity. Cancer Cell. 24(6). 695–709. 477 indexed citations breakdown →

12.

Casazza, Andrea, Giusy Di Conza, Mathias Wenes, et al.. (2013). Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment. Oncogene. 33(14). 1743–1754. 203 indexed citations

13.

Tugues, Sònia, Satoshi Honjo, Christian König, et al.. (2012). Genetic Deficiency in Plasma Protein HRG Enhances Tumor Growth and Metastasis by Exacerbating Immune Escape and Vessel Abnormalization. Cancer Research. 72(8). 1953–1963. 36 indexed citations

14.

Oliveira, Rodrigo Leite de, Sofie Deschoemaeker, Anne‐Theres Henze, et al.. (2012). Gene-Targeting of Phd2 Improves Tumor Response to Chemotherapy and Prevents Side-Toxicity. Cancer Cell. 22(2). 263–277. 94 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact